JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB187831

Anti-Bcr-abl antibody [7C6]

Be the first to review this product! Submit a review

|

(11 Publications)

Mouse Recombinant Monoclonal Bcr-abl antibody. Suitable for ICC/IF, WB and reacts with Human samples. Cited in 11 publications.

View Alternative Names

BCR ABL fusion, BCR ABL fusion protein, BCR/ABL fusion, BCR/ABL fusion protein, BCRe18/ABL1e3 fusion protein, Bcr/c abl oncogene protein, Breakpoint cluster region, CML

2 Images
Immunocytochemistry/ Immunofluorescence - Anti-Bcr-abl antibody [7C6] (AB187831)
  • ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Anti-Bcr-abl antibody [7C6] (AB187831)

Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 fixed K562 (human chronic myelogenous leukemia lymphoblast) cells labeling Bcr-abl with ab187831 at 1/250 dilution, followed by ab150113 Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) secondary antibody at 1/1000 dilution (Green). Confocal image showing strongly cytoplasmic staining in K-562 cell line. The nuclear counter stain id DAPI (Blue). Tubulin is detected using ab179513 Anti-beta Tubulin rabbit monoclonal antibody at 1/200 dilution, followed by ab150080 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 594) at 1/500 dilution (Red).

The negative controls are as follows :
-ve control 1 : ab187831 at 1/250 dilution, followed by ab150080 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 594) secondary at 1/500 dilution.
-ve control 2 : Primary (ab179513) at 1/200 dilution, followed by ab150113 Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) secondary at 1/1000 dilution.

Western blot - Anti-Bcr-abl antibody [7C6] (AB187831)
  • WB

Unknown

Western blot - Anti-Bcr-abl antibody [7C6] (AB187831)

Blocking and diluting buffer and concentration : 5% NFDM/TBST

Lysates should be non-boiled as boiling may cause protein aggregates.

Exposure time : 59 seconds

All lanes:

Western blot - Anti-Bcr-abl antibody [7C6] (ab187831) at 1/1000 dilution

Lane 1:

K562 (human chronic myelogenous leukemia lymphoblast), whole cell lysate at 10 µg

Lane 2:

Jurkat (human T cell leukemia T lymphocyte), whole cell lysate at 10 µg

Lane 3:

HEK-293 (human embryonic kidney epithelial cell), whole cell lysate at 10 µg

Secondary

All lanes:

Goat anti-Mouse IgG (H+L), Peroxidase conjugated at 1/10000 dilution

Predicted band size: 197 kDa

Observed band size: 142 kDa,210 kDa

false

  • Carrier free

    Anti-Bcr-abl antibody [7C6] - BSA and Azide free

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

7C6

Isotype

IgG2a

Carrier free

No

Reacts with

Human

Applications

WB, ICC/IF

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Epitope

Cells from immunized Balb/c mice were fused with the P3X63Ag8 myeloma cell line.

Specificity

This antibody recognizes an epitope within the amino acid sequence SSINEEITPRRQS of Bcr/Abl.

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/250", "ICCIF-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>" }, "Mouse": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "" }, "Rat": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "" } } }
style
left-column

Product details

This product has switched from a hybridoma to recombinant production method on 08th March 2021.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The Bcr-abl fusion protein also known as BCR-ABL or BCR/c-ABL results from a genetic abnormality where parts of the BCR and ABL genes combine together. This fusion occurs on chromosome 22 known as the Philadelphia chromosome leading to a well-known oncogenic protein with a molecular mass of approximately 210 kDa. The Bcr-abl is primarily expressed in hematopoietic cells and plays a critical role in cellular proliferation and survival. The protein's kinase domain derived from c-ABL exhibits tyrosine kinase activity regulating downstream signaling pathways involved in cellular growth and division.
Biological function summary

Bcr-abl significantly alters normal cell functions by constantly activating signals that drive cell cycle progression and inhibit apoptosis. This protein forms a complex with various signaling molecules enhancing proliferative signals within the cell. The presence of BCR/ABL leads to abnormal interaction with cell cycle regulators and contributes to dysregulated growth characteristic of cancerous cells. Through these interactions Bcr-abl affects DNA repair processes and cytoskeletal remodelling both of which are critical for maintaining genomic stability and cellular integrity.

Pathways

Bcr-abl influences multiple signaling cascades prominently including the PI3K-AKT and RAS-RAF-MEK-ERK pathways. These pathways are pivotal for transmitting growth factor signals that promote cell survival and proliferation. BCR-ABL activates these pathways independently of growth factor binding which leads to uncontrolled proliferation and resistance to apoptosis. Additionally Bcr-abl interacts with proteins such as GRB2 and SHC which are parts of these signaling networks further amplifying growth and survival signals in affected cells.

Bcr-abl is strongly associated with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). These malignancies arise due to the continuous activity of the aberrant Bcr-abl protein which leads to the overproduction of malignant leukocytes. The disease progression in CML illustrates a link between the Bcr-abl expression and the transformation of normal hematopoietic stem cells into leukemic cells. Furthermore this protein relates to the development of leukemias by interacting with downstream effectors like STAT5 which aids in the transcription of anti-apoptotic genes further contributing to cancer cell survival and proliferation.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

See full target information Bcr-abl
style
left-column

Publications (11)

Recent publications for all applications. Explore the full list and refine your search

Cell death & disease 16:282 PubMed40221405

2025

Dysregulation of sphingolipid metabolism contributes to the pathogenesis of chronic myeloid leukemia.

Applications

Unspecified application

Species

Unspecified reactive species

Yinyin Xie,Qinghua Zeng,Zhiwei Chen,Jiachun Song,Fuhui Wang,Dan Liu,Xiaojian Sun,Yuanliang Zhang,Qiuhua Huang

eLife 12: PubMed38865175

2024

RAPSYN-mediated neddylation of BCR-ABL alternatively determines the fate of Philadelphia chromosome-positive leukemia.

Applications

Unspecified application

Species

Unspecified reactive species

Mengya Zhao,Beiying Dai,Xiaodong Li,Yixin Zhang,Chun Qiao,Yaru Qin,Zhao Li,Qingmei Li,Shuzhen Wang,Yong Yang,Yijun Chen

Cell death & disease 14:799 PubMed38057328

2023

Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.

Applications

Unspecified application

Species

Unspecified reactive species

Melina Vogt,Niklas Dienstbier,Julian Schliehe-Diecks,Katerina Scharov,Jia-Wey Tu,Philip Gebing,Julian Hogenkamp,Berna-Selin Bilen,Silke Furlan,Daniel Picard,Marc Remke,Layal Yasin,David Bickel,Munishikha Kalia,Alfredo Iacoangeli,Thomas Lenz,Kai Stühler,Aleksandra A Pandyra,Julia Hauer,Ute Fischer,Rabea Wagener,Arndt Borkhardt,Sanil Bhatia

International journal of oncology 58:238-250 PubMed33491750

2021

Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib.

Applications

Unspecified application

Species

Unspecified reactive species

Tereza Hrdinova,Ondrej Toman,Jiri Dresler,Jana Klimentova,Barbora Salovska,Petr Pajer,Oldrich Bartos,Vaclava Polivkova,Jana Linhartova,Katerina Machova Polakova,Hana Kabickova,Barbora Brodska,Matyas Krijt,Jan Zivny,Daniel Vyoral,Jiri Petrak

Oxidative medicine and cellular longevity 2021:8877460 PubMed33532040

2021

Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Lanzhu Li,Wenjie Liu,Qian Sun,Han Zhu,Ming Hong,Sixuan Qian

Theranostics 11:2691-2705 PubMed33456567

2021

KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia.

Applications

Unspecified application

Species

Unspecified reactive species

Chengwan Zhang,Li Shen,Yifu Zhu,Ran Xu,Zhikui Deng,Xiaoning Liu,Yihan Ding,Chunling Wang,Yuye Shi,Liye Bei,Dongping Wei,Rick F Thorne,Xu Dong Zhang,Liang Yu,Song Chen

Nature biomedical engineering 5:41-52 PubMed32719513

2020

Tracking the expression of therapeutic protein targets in rare cells by antibody-mediated nanoparticle labelling and magnetic sorting.

Applications

Unspecified application

Species

Unspecified reactive species

Mahmoud Labib,Zongjie Wang,Sharif U Ahmed,Reza M Mohamadi,Bill Duong,Brenda Green,Edward H Sargent,Shana O Kelley

Oncology letters 13:2059-2070 PubMed28454362

2017

Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells.

Applications

WB

Species

Unspecified reactive species

Cheng Zhang,Xi Zhang,Shi-Jie Yang,Xing-Hua Chen

Leukemia 4:745-50 PubMed2232885

1990

BCR-ABL and BCR proteins: biochemical characterization and localization.

Applications

Unspecified application

Species

Unspecified reactive species

S Dhut,T Chaplin,B D Young

Oncogene 3:561-6 PubMed3078961

1988

Identification of two normal bcr gene products in the cytoplasm.

Applications

Unspecified application

Species

Unspecified reactive species

S Dhut,E L Dorey,M A Horton,T S Ganesan,B D Young
View all publications
style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB8227

Anti-beta Actin antibody - Loading Control

BOND RX™ Validated|Lab Essentials

Western blot - Anti-beta Actin antibody - Loading Control (AB8227)

  • 5
  • 104
Secondary Antibodies

AB150113

Goat Anti-Mouse IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) (AB150113)

  • 5
  • 15
Primary Antibodies

AB40660

Anti-SRC Family (phospho Y418) antibody [EP503Y]

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Anti-SRC Family (phospho Y418) antibody [EP503Y] (AB40660)

  • 4
  • 2
Primary Antibodies

AB272701

Anti-ABL1 antibody [EPR23406-32] - BSA and Azide free

KO Validated|RabMAb|Recombinant

Flow Cytometry (Intracellular) - Anti-ABL1 antibody [EPR23406-32] - BSA and Azide free (AB272701)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com